sifalimumab

mAbexperimental

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a. — Wikipedia

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mdx-1103
  • medi 545
  • medi-545
  • medi-545
  • sifalimumab
  • sifalimumab
  • sifalimumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01283139Phase 2Mar 1, 2011MedImmune
NCT00979654Phase 2Aug 1, 2010MedImmune, PPD
NCT01031836Phase 2Nov 1, 2009AstraZeneca, Keio University, MedImmune, University of Occupational and Environmental Health, Japan
NCT00657189Phase 2Jul 1, 2008MedImmune
NCT00533091Phase 1Apr 1, 2008MedImmune
NCT00482989Phase 1Jun 1, 2007MedImmune
NCT00472758Phase 1Feb 1, 2007MedImmune
NCT00299819Phase 1Mar 1, 2006MedImmune
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MedImmuneFor profit8722006
AstraZenecaFor profit1112009
Keio UniversityAcademic/Hospital1012009
PPDFor profit1012010
University of Occupational and Environmental Health, JapanAcademic/Hospital1012009
5 organizations
Page 1 / 1